A paper published in Nature Communications says that scientists at the Peter Doherty Institute for Infection and Immunity in Melbourne have tapped into mRNA technology...
Lenacapavir, injectable twice a year, is developed by the US-based biopharmaceutical company Gilead Sciences, Inc. as a pre-exposure prophylaxis (PrEP) drug. These drugs prevent...